Abstract: BACKGROUND: Although surgical resection is the standard of care for early-stage non-small cell lung cancer, frailty influences treatment decisions. We evaluated the …
Abstract: BACKGROUND: Germline pathogenic variants can inform targeted therapy for metastatic prostate cancer (mPC), and improve cancer early detection and risk reduction for …
Abstract: Background: Black individuals have higher incidence and mortality rates of prostate cancer than White individuals, and existing literature on treatment sequencing …
Abstract: INTRODUCTION: Treatment of metastatic hormone sensitive prostate cancer (mHSPC) has traditionally included combination therapy of androgen deprivation therapy (ADT) with …
Abstract: Importance: The choice of first line hormonal therapy in metastatic hormone-sensitive prostate cancer (mHSPC) is often based on comorbidities or physician preference due …
Abstract: Background: There is a complex relationship between body weight and survival in prostate cancer. While increased BMI is associated with increased prostate cancer …
Abstract: BACKGROUND: Agent Orange exposure (AOE) is considered a presumptive cause of prostate cancer (PCa) in the Veterans Affairs (VA) population; however, cohort studies …
Abstract:Several stakeholders have advocated for regionalization of lung cancer surgery to high-volume hospitals. Although regionalization may hold promise for improving …
Abstract: Purpose: This study introduces an integrated approach using structured and unstructured data from an electronic health record to identify and characterize patient …
Abstract: BACKGROUND: Abiraterone and enzalutamide are second generation androgen receptor pathway inhibitors (ARPIs) used to treat advanced or metastatic prostate cancer. Without …
Abstract: Introduction: Serum Protein Electrophoresis (SPEP) is a frequently ordered diagnostic test when there is suspicion of plasma cell dyscrasia, based on clinical or …
Abstract: BACKGROUND: Comorbid diseases influence patient outcomes, yet little is known about how comorbidities interact with treatments for metastatic castrate-resistant prostate …